Regulatory Scrutiny: PepGen's Myotonic Dystrophy Trial Faces FDA Obstacle
FDA's Concerns Regarding Preclinical Data
The U.S. Food and Drug Administration recently imposed a partial clinical hold on PepGen's FREEDOM2-DM1 clinical trial. This action was primarily driven by unresolved questions concerning the preclinical pharmacology and toxicology studies associated with the drug. The agency's decision emphasizes the critical importance of comprehensive safety and efficacy data before new treatments can proceed without hindrance.
FREEDOM2-DM1 Trial and Previous Submissions
The FREEDOM2 study is designed as a Phase 2 trial, involving multiple ascending doses of PGN-EDODM1, specifically targeting patients diagnosed with myotonic dystrophy type 1 (DM1). It is noteworthy that the FDA's partial hold did not raise any issues with the blinded clinical data that had been previously submitted from the Phase 1 FREEDOM study, which had initially paved the way for the FREEDOM2 trial's commencement in the United States.
PepGen's Response and Ongoing Dialogue with the FDA
In response to the FDA's regulatory action, PepGen is actively engaged in submitting additional analyses. This includes providing the recently unblinded data from its FREEDOM study, in an effort to address the agency's concerns and facilitate the lifting of the partial clinical hold. This ongoing communication is a standard part of the drug development process, aiming to resolve regulatory questions and ensure patient safety.
Focus Shift to Myotonic Dystrophy Type 1
Prior to this development, in May 2025, PepGen made a strategic decision to discontinue its PGN-EDO51 development program. This program was focused on Duchenne muscular dystrophy, and its cessation marked a shift in the company's research and development priorities towards other rare disease candidates, particularly myotonic dystrophy type 1.
Reasons for Discontinuing the Duchenne Program
The discontinuation of the Duchenne muscular dystrophy program was a direct result of the dystrophin protein levels observed in the 10 mg/kg cohort of its CONNECT1-EDO51 study. The levels measured did not meet the company's expectations for patients amenable to exon 51 skipping, leading to the strategic redirection of resources.
International Progress in Clinical Trials
Despite the challenges faced in the U.S., PepGen has achieved regulatory clearance to initiate the FREEDOM2 study in several other countries, including South Korea, Australia, and New Zealand. Furthermore, the dosing of the 10 mg/kg cohort is currently underway in the United Kingdom and Canada, indicating continued global progress for the trial.
Anticipated Data Releases for FREEDOM2
Looking ahead, PepGen has outlined its plans for upcoming data releases from the FREEDOM2 trial. The company anticipates reporting data from the 5 mg/kg cohort in the first quarter of 2026, followed by data from the 10 mg/kg cohort in the latter half of 2026. These releases are crucial for evaluating the drug's performance and guiding future development.
Market Performance and Technical Analysis of PepGen's Stock
Currently, PepGen's stock is experiencing a bearish trend, trading significantly below its 20-day and 100-day simple moving averages. The stock's position closer to its 52-week lows reflects ongoing challenges and market uncertainty. Technical indicators such as a neutral Relative Strength Index (RSI) at 50.00 and a bearish Moving Average Convergence Divergence (MACD) at -0.10, below its signal line at 0.05, suggest mixed momentum and an unpredictable short-term outlook for investors.
Key Resistance and Support Levels
For investors, key resistance is identified at $7.50, while a crucial support level is established at $4.50. These figures are important for understanding potential price movements and risk management.
Analyst Consensus and Recent Ratings
The broader analyst community maintains a "Buy" rating for PepGen, with an average price target of $13.25. Recent analyst actions include Oppenheimer initiating coverage with an "Outperform" rating and a $15.00 target, and Guggenheim raising its target to $7.00 while maintaining a "Buy" rating. These assessments reflect a degree of optimism despite the current regulatory headwinds.
Premarket Stock Movement
On Thursday, PepGen shares saw a premarket decline of 14.20%, trading at $5.80. This dip underscores the immediate impact of the FDA's partial clinical hold on investor confidence and the company's valuation.